Does the patient need a wearable cardioverter‑defibrillator (LifeVest) with an ejection fraction of 35‑40%?

No, a LifeVest is generally NOT indicated for an EF of 35-40%

A patient with an ejection fraction of 35-40% does not meet the standard criteria for wearable cardioverter-defibrillator (WCD/LifeVest) therapy, as this device is primarily indicated for patients with LVEF ≤35% during specific high-risk transitional periods.

Key Guideline Thresholds

The 2022 AHA/ACC/HFSA guidelines and 2017 VA/SCD guidelines establish clear EF cutoffs for device therapy 1, 2:

• Permanent ICD indication: LVEF ≤35% (after optimization of guideline-directed medical therapy and appropriate waiting periods)
• WCD consideration: LVEF ≤35% during transitional high-risk periods

Your patient with EF 35-40% falls above these thresholds.

When WCD Is Actually Indicated

The WCD receives a Class IIb recommendation (may be reasonable) for specific scenarios where LVEF is ≤35% 2:

Accepted Indications:

• Within 40 days post-MI with LVEF ≤35% (ICD contraindicated during this period)
• Newly diagnosed non-ischemic cardiomyopathy with LVEF ≤35% awaiting reassessment after GDMT optimization
• Recent revascularization (within 90 days) with LVEF ≤35%
• Active myocarditis or systemic infection with LVEF ≤35%
• Bridge after ICD explantation (e.g., for infection) in patients with prior sustained VA
• Bridge to cardiac transplantation

Your Patient's Situation:

With EF 35-40%, your patient:

• Does not meet criteria for primary prevention ICD (needs LVEF ≤35%)
• Does not meet criteria for WCD bridging therapy
• Should focus on optimizing GDMT and monitoring for further EF changes

Clinical Context Matters

If EF is Trending Down:

If this represents a decline from previously normal function:

• Aggressively optimize heart failure medications (beta-blocker, ACE-I/ARB/ARNI, MRA, SGLT2i)
• Reassess LVEF in 3 months 1
• If EF drops to ≤35%, then consider device therapy

If EF is Improving:

Research shows 39-63% of patients with initially reduced EF improve to >35% with optimal medical therapy 3, 4, 5, 6:

• Continue GDMT optimization
• Serial echocardiographic monitoring
• WCD would be unnecessary if trajectory is upward

Important Caveats

Exception - Genetic Arrhythmogenic Cardiomyopathy: The 2022 guidelines note that ICD may be reasonable for genetic arrhythmogenic cardiomyopathy with high-risk features when EF ≤45% 1. This is a specific exception requiring genetic diagnosis and additional risk stratification.

Measurement Variability: Ensure EF measurement is accurate:

• Consider cardiac MRI if echocardiographic windows are poor
• EF measurements can vary by 5-10% between studies
• If borderline (35-36%), repeat imaging may be warranted

Bottom Line Algorithm

For EF 35-40%:

1. Optimize GDMT (all four pillars if HFrEF)
2. No WCD indicated at this EF range
3. Reassess EF in 3 months after medication optimization
4. If EF drops to ≤35%: Consider ICD (if >40 days post-MI and optimized GDMT) or WCD (if within contraindication windows)
5. If EF improves to >40%: Continue medical management without device therapy

The evidence is clear that WCD therapy has not demonstrated mortality benefit in randomized trials 7, and its role is limited to bridging high-risk periods in patients with LVEF ≤35% who are temporarily ineligible for permanent ICD implantation 2.